Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initial:** 5 mg twice daily.
* **Maintenance:** Increase dose every week as tolerated to achieve clinical response. Typical maintenance dose is 5-10 mg twice daily.
* **Maximum:** Generally **20 mg twice daily** (40 mg/day). Doses up to 30 mg twice daily (60 mg/day) have been used in clinical trials.
## Pediatric Dosing
* **2 years and older:**
* **Initial:** 5 mg twice daily.
* **Maintenance:** Increase dose every week as tolerated to achieve clinical response. Typical maintenance dose is 5-10 mg twice daily.
* **Maximum:** Generally **10 mg twice daily** (20 mg/day). Doses up to 20 mg twice daily (40 mg/day) have been used in clinical trials.
* **Under 2 years:** Safety and efficacy not established. Use with caution, starting at the lowest dose and titrating slowly.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; may require dose reduction.
* **Renal Impairment:** Use with caution; may require dose reduction.
## Contraindications
* Hypersensitivity to clobazam or any component of the formulation.
* Severe hepatic impairment.
## Adverse Effects
**Most Common:** Somnolence, saliva or sputum increase, constipation, decreased appetite, fatigue, aggression.
**Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior and ideation, central nervous system (CNS) depression, paradoxical reactions, withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedatives/hypnotics):** Increased risk of sedation, respiratory depression, and profound CNS depression.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Inhibitors can increase clobazam levels, while inducers can decrease them.
* **CNS Stimulants:** May reduce the efficacy of stimulants.
* **Antiepileptic Drugs (AEDs):** Monitor for increased AED levels or toxicity with concomitant use.
## Monitoring
* Monitor for seizure frequency and severity.
* Monitor for signs of somnolence, sedation, and CNS depression.
* Monitor for signs of suicidal behavior or ideation.
* Monitor for withdrawal symptoms upon discontinuation.
* Consider therapeutic drug monitoring if efficacy is suboptimal or toxicity is suspected.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy for LGS.
* Withdrawal symptoms can occur upon abrupt discontinuation, so taper slowly.
* Patients may experience paradoxical reactions, such as increased seizure activity or aggression.
* Warn patients about the potential for somnolence and impaired cognitive/motor performance, advising caution with activities requiring alertness.
***
*This information is intended for healthcare professionals. Always verify current prescribing information and consult relevant guidelines before making clinical decisions. Pediatric dosing may vary based on local protocols and specific patient factors.*
